血管紧张素II 1型受体rs5186基因变异预测新发NAFLD及相关高血压:膳食脂肪诱导促炎细胞活化的作用
在314例健康非肥胖、非糖尿病、非高血压、胰岛素敏感人群中随访9.8年,AGTR1 A1166C变异预测新发NAFLD(OR 1.67,95%CI 1.26-2.21)和高血压(OR 1.49,95%CI 1.12-2.63)。78例活检证实的非糖尿病NAFLD患者及对照的横断面分析显示,C等位基因携带者餐后VLDL蓄积、resistin、MCP-1、calprotectin反应及单核细胞NF-κB活化增高,脂联素反应减弱。
要点
- AGTR1 A1166C变异预测9.8年新发NAFLD和高血压。
- C等位基因携带者胰岛素抵抗更高,餐后富含甘油三酯和胆固醇的VLDL蓄积。
- C等位基因携带者餐后resistin、MCP-1、calprotectin反应及NF-κB活化增高,脂联素反应减弱。
核心结论
- AGTR1 A1166C变异至少部分通过调节脂肪摄入后的脂肪因子、趋化因子和促炎细胞活化,影响NAFLD的肝脏疾病、胰岛素抵抗和内皮功能障碍。
研究设计与样本
- 人群为基础研究,随访314例健康非肥胖、非糖尿病、非高血压、胰岛素敏感的参与者,检测AGTR1 rs5186 A1166C变异、脂肪因子谱、炎症和内皮功能障碍标志物。
- 独立队列78例活检证实的非糖尿病NAFLD患者和对照,进行口服葡萄糖耐量试验及最小模型分析葡萄糖稳态,以及口服脂肪耐量试验测定血浆脂蛋白、脂肪因子、MCP-1、calprotectin和循环单核细胞核因子-κB活化。
主要发现
- AGTR1 A1166C多态性预测9.8年新发NAFLD(OR 1.67,95%CI 1.26-2.21)和高血压(OR 1.49,95%CI 1.12-2.63),以及9年心血管疾病风险及内皮功能障碍标志物升高。
- 横断面队列中,AGTR1 C等位基因携带者胰岛素抵抗更高。
- 尽管空腹血脂谱相当,AGTR1 C等位基因携带者显示餐后富含甘油三酯和胆固醇的VLDL脂蛋白蓄积,resistin、MCP-1和calprotectin反应及单核细胞核因子-κB活化更高,脂肪餐后脂联素反应减弱。
- 上述指标预测肝脏组织学、肝细胞凋亡活化、胰岛素抵抗和内皮功能障碍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hypertension has been linked to the presence and severity of nonalcoholic fatty liver disease (NAFLD) through unclear mechanisms. The gain-of-function rs5186 A1166C variant in angtiotensin receptor type 1 (AGTR1) gene has been linked to hypertension, cardiovascular disease and metabolic syndrome. We assessed the impact of AGTR1 A1166C variant on NAFLD incidence and severity and on glucose and lipid metabolism and explored the underlying mechanisms. METHODS: We followed up 314 healthy nonobese, nondiabetic, nonhypertensive, insulin-sensitive participants in a population-based study, characterized for AGTR1 rs5186 A1166C variant, adipokine profile, inflammatory and endothelial dysfunction markers. An independent cohort of 78 biopsy-proven nondiabetic NAFLD patients and controls underwent an oral glucose tolerance test with Minimal Model analysis of glucose homeostasis, and an oral fat tolerance test with measurement of plasma lipoproteins, adipokines, MCP-1, calprotectin, and nuclear factor-κB activation in circulating mononuclear cells. RESULTS: AGTR1 A1166C polymorphism predicted 9.8-year incident NAFLD (odds ratio: 1.67, 95% CI: 1.26-2.21) and hypertension (odds ratio: 1.49, 95% CI: 1.12-2.63) and 9-year increase in cardiovascular disease risk and endothelial dysfunction markers. In the cross-sectional cohort, AGTR1 C allele carriers had higher insulin resistance. Despite comparable fasting lipid profiles, AGTR1 C allele carriers showed postprandial triglyceride-rich and cholesterol-rich VLDL lipoprotein accumulation, higher resistin, MCP-1 and calprotectin responses and nuclear factor-κB activation in mononuclear cells, and a blunted postprandial adiponectin response to fat, which predicted liver histology, hepatocyte apoptosis activation, insulin resistance, and endothelial dysfunction. DISCUSSION: AGTR1 A1166C variant affects liver disease, insulin resistance, and endothelial dysfunction in NAFLD, at least in part by modulating adipokine, chemokine, and pro-inflammatory cell activation in response to fat ingestion.
引用
- Musso G, Saba F, Cassader M, et al. Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. Am J Gastroenterol. 2019. PMID: 30920415. doi:10.14309/ajg.0000000000000154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。